Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata

Roseborough, Ingrid E.; Lee, Hester; Chwalek, Jennifer; Stamper, Robert L.; Price, Vera H.

doi:10.1016/j.jaad.2008.08.029

Cited by 57 publications

(44 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intriguing point in the current study is the assessment of using PG analogues for scalp AA, rather than its usual trials on AA of the eyelashes and eyebrows [6,7,8,9,10,11,12] that yielded conflicting results. Recently, Khidhir et al [16] demonstrated that the PG-related glaucoma drug bimatoprost can stimulate growth in non-eyelash hair follicles in mice in vivo and in human scalp hair follicles in dynamic organ culture, mirroring the stimulation of eyelashes known to occur in vivo.…”

Section: Discussionmentioning

confidence: 99%

“…The results of the current study are in accordance with several others [11,12,21] which documented both the efficacy and safety of this line of therapy in the treatment of such cases. On the other hand, several other studies [8,9,10] argued against the postulated value of using PG analogues in the treatment of AA, as they demonstrated a lack of efficacy. Several points could offer an explanation for this discrepancy.…”

Section: Discussionmentioning

confidence: 99%

“…Accordingly, several studies have been conducted to explore the potentials of this therapeutic modality. However, they yielded conflicting results and were mainly focused on AA of the eyelashes [8,9,10,11,12]. This debate triggered the conduction of the current study, a trial to assess the efficacy and safety of bimatoprost 0.03% solution (prostamide analogue) in comparison to the well-documented topical corticosteroid therapy in the treatment of limited patchy AA of the scalp.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

et al. 2015

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is an immune-mediated disease that targets anagen hair follicles. Despite various therapeutic options, there is no cure for AA. Prostaglandin analogues have been recognized as being capable of inducing hypertrichosis. Objective: To compare the efficacy and safety of bimatoprost to those of corticosteroid in the treatment of scalp AA. Methods: Thirty adult patients with patchy AA (S₁) were included. Two AA patches were randomly assigned to treatment either by mometasone furoate 0.1% cream once daily (area A) or bimatoprost 0.03% solution twice daily (area B) for 3 months. Patients were assessed using the Severity of Alopecia Tool (SALT) scoring system for hair re-growth. Results: All responding AA patches showed significant reduction in their SALT score after therapy. Area B demonstrated significantly better results regarding rapidity of response in weeks, percentage of hair re-growth and side effects compared to area A. Conclusion: Bimatoprost solution represents a therapeutic option for scalp AA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although reports about effective clinical response have been found [36], two randomized controlled studies demonstrated an efficacy of topical latanoprost in the AA [37][38][39].…”

Section: Topical Prostaglandin Analoguesmentioning

confidence: 99%

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

“…These treatments are typically used for open-angle glaucoma however eyelash hypertrichosis was noted as a pleasing side effect. Response rates have been variable with one study showing 45% complete or moderate regrowth of eyelashes over 2 years using latanoprost whilst another study showed no significant response to latanoprost or bimatoprost over 16 weeks [32,33]. Clinicians should recommend protective glasses to patients with extensive and complete loss of eyelashes to protect the eyes from dust, grit and debris.…”

Section: Treating Eyelash Alopeciamentioning

confidence: 99%

Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata

Sinclair¹

2014

Hair Therap Transplantat

View full text Add to dashboard Cite

Alopecia Areata (AA) is a common non-scarring alopecia that usually presents as well circumscribed patches of sudden hair loss that affects 0.1-0.2% of the population. The aetiology is thought to be both genetic and autoimmune in nature. 139 single nucleotide polymorphisms have been identified in 8 regions of the genome and are found to be associated with T cells or the hair follicle. Furthermore, patients with AA have been found to have an increased frequency of hair follicle-specific auto-antibodies. The diagnosis of AA is usually made on clinical grounds, and further investigations are not usually indicated. Intralesional corticosteroids remain the treatment of choice. Systemic steroids are also highly effective; however side effects make them less desirable to both patients and physicians. Other treatment options available include anthralin, minoxidil, topical immunotherapy and these treatments will be discussed further in depth in this chapter. The morbidity of AA is largely psychological; therefore the successful treatment of AA should include focusing on the improvement of the psychological impact of this condition.

show abstract

Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata

Cited by 57 publications

References 5 publications

Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

New Modalities in the Treatment of Refractory Alopecia Areata

Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata

Contact Info

Product

Resources

About